Q&A with Pramodkumar P Gupta

Meet Pramodkumar, an Assistant Professor who is carrying out bioinformatics for molecular modeling and computer-aided drug discovery.

Go to the profile of Dr Alison Halliday
Jul 10, 2018
1
Comment

What is your full name, job title and where do you work?

Pramodkumar P Gupta, Assistant Professor, D Y Patil Deemed to be University, School of Biotechnology and Bioinformatics, Navi-Mumbai, Maharashtra, India.

What are your main research interests?

I carry out bioinformatics for molecular modelling and computer-aided drug discovery. Currently, I am working on understanding the off-target effects of an anti-kinase cancer drug.

Describe your work in a tweet

My work deals with the in-silico design and development of small molecule kinase inhibitors, pathway modelling and analysis.

What big projects are you working on right now?

Small molecule kinase inhibitors, anti-diabetic small molecules, off-target effects of kinase inhibitors.

Who do you collaborate with?

Academic and research organization (Amity University – India, Mumbai Education Trust-India, Bharati Vidya Peeth – India, Vilnius University – Lithuania).

Tell us a bit about your career so far

I have 10 years of experience in teaching and research in bioinformatics and chemoinformatics (3D structure modelling, drug discovery, pathway modelling and analysis). I am an Erasmus Mundus doctoral fellow and have completed my work “Kinase off-target to RH1 drug” at the Proteomic Center, Vilnius University in Lithuania.

What are you most proud of?

Contributing to science and society.

What’s your interest in the cancer-immune setpoint?

Data annotation from large literature resources and computational modelling in therapeutic application.

What do you hope it will achieve?

A high-quality centralised data resource enabling the utmost knowledge extraction on our understanding of cancer and the immune system. The design, modelling and analysis of novel cancer immune modulators will help us to achieve better therapeutics in terms of reducing toxicity and widening the response to treatment, so they can benefit more patients.

What advice do you have for others working in the field?

Work in collaboration will help our “Cancer Immunotherapy” community to foster our expertise in achieving our therapeutic success.

What do you do to wind down?

I eat healthy and move around for short walks.

Tell us something unusual about yourself

I like to work in collaboration; besides my work, I enjoy good cuisine of Indian food!

Go to the profile of Dr Alison Halliday

Dr Alison Halliday

Community Manager, Nature Research

Molecular Biologist turned freelance science communicator, with 10 year's experience at Cancer Research UK.

1 Comments

Go to the profile of Dan Chen MD PhD
Dan Chen MD PhD about 1 month ago

Dr Gupta- I was very excited to see your interests around data annotation from large literature sources and the cancer immune set point. In many areas, but particularly the cancer immunology and immunotherapy, we are in the beneficial situation where massive amounts of data are being generated to help us better understand the underlying biology. However, as a community, we struggle with how to comprehend and assemble all of this information. Would love to hear your thoughts on how we might better utilize frameworks, such as the cancer immune set point and data annotation from these rapidly growing datasets!